

Haematologica  
HAEMATOL/2016/159087  
Version 3

Genetic Polymorphism at BCL2 as a predictor for R-CHOP efficacy in  
patients with diffuse large B-cell lymphoma

Morteza Bashash, Joseph M. Connors, Randy D. Gascoyne, Barbara  
Meissner, Johanna M. Schuetz, Stephen Leach, Graham W. Slack,  
Brian R. Berry, Howard Hu, Laurie H. Sehn, Angela R. Brooks-Wilson,  
and John J. Spinelli

Disclosures: JMC, LHS, RDG have received institutional research funding from Roche  
GWS: Honoraria from Janssen Pharmaceuticals LHS: Honoraria from Roche/Genentech,  
Janssen Pharmaceuticals, Celgene; Consultancy/Advisory role: Roche/Genentech,  
Janssen Pharmaceuticals, Celgene. RDG: Honoraria from Roche/Genentech, Celgene and  
Janssen Pharmaceuticals; Consultancy/Advisory role: Roche/Genentech, Celgene,  
Janssen Pharmaceuticals, NanoString Technologies Patents, Royalties or other Intellectual  
Property: Named inventor on a pending patent that has been licensed to NanoString  
Technologies. MB, ABW, BM, BRB, HH, JJS, JMS and SL have no relationships to  
disclose

Contributions: Conception and design: MB, JJS, ABW, JMC, RDG Manuscript writing: MB,  
JJS, ABW, JMC, RDG Pathology review: RDG, GDS, BRB Collection and assembly of  
data: JJS, ABW, MB, BM, BRB, GWS, JMS, JMC, LHS, RDG and SL Data analysis and  
interpretation: JJS, ABW, MB, JMC, RDG, HH, JMS Statistical analysis: MB, JJS, HH, JMS  
Final approval of manuscript: All authors